Neutralizing antibodies (nAbs) are a high priority for vaccines that aim to prevent the
acquisition of HIV-1 infection. Vaccine effectiveness will depend on the extent to which …

Broadly neutralizing antibodies (NAbs) such as those generated in chronic human
immunodeficiency virus type 1 (HIV-1) infection are considered a key component for an …

Standardized assessments of HIV-1 vaccine-elicited neutralizing antibody responses are
complicated by the genetic and antigenic variability of the viral envelope glycoproteins …

Induction of broadly cross-reactive antiviral humoral responses with the capacity to target
globally diverse circulating strains is a key goal for HIV-1 immunogen design. A major gap in …

Subtype B HIV-1 has been the primary driver of the HIV-1 epidemic in the United States (US)
for over forty years and is also a prominent subtype in the Americas, Europe, Australia, the …

In the search for effective immunologic interventions to prevent and treat HIV-1 infection,
standardized reference reagents are a cost-effective way to maintain robustness and …

The HIV-1 pandemic remains a major burden on global public health and a vaccine to
prevent HIV-1 infection is highly desirable but has not yet been developed. Among the many …

The restricted neutralization breadth of vaccine-elicited antibodies is a major limitation of
current human immunodeficiency virus-1 (HIV-1) candidate vaccines. In order to permit the …

To better understand the dynamics of HIV-specific neutralizing antibody (NAb), we examined
associations between viral genetic diversity and the NAb response against a multi-subtype …

The implications of patterns in HIV diversity for neutralizi... : Current Opinion in HIV and AIDS
The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility …